A high proportion of phase 3 trials which evaluate lung cancer patients in various settings do not assess quality of life (QoL). This is not only the case in studies initiated by the pharmaceutical industry or investigator-initiated trials, but also in non-profit trials and the metastatic setting, despite symptom burden and limited life expectancy. Also, timely inclusion of QoL results in primary publications has been significantly worsening in recent years, which is particularly frequent in papers published in high impact factor journals.
Reale et al. described the prevalence and heterogeneity of QoL reporting in lung cancer phase 3 trials. This was done using a selection of all primary publications of lung cancer phase 3 trials evaluating anticancer drugs published between 2012-2018 by 11 major journals. This resulted in 122 publications which could be assessed.
It was found that QoL was not listed among endpoints in 32.0% of publications. The pro...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« EGFR TKI Retreatment Effective after Earlier Discontinuation Next Article
Targeted therapies for NMOSD in development »
Table of Contents: WCLC 2019
Screening, Detection, and Diagnosis
Non-Small-Cell Lung Cancer
Other Thoracic Malignancies
Phase 3 Trial Updates
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.